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Abstract
Background: Quantitative SPECT imaging in targeted radionuclide therapy with
lutetium-177 holds great potential for individualized treatment based on dose
assessment. The establishment of dose-effect relations requires a standardized method for
SPECT quantification. The purpose of this multi-center study is to evaluate quantitative
accuracy and inter-system variations of different SPECT/CT systems with
corresponding commercially available quantitative reconstruction algorithms. This
is an important step towards a vendor-independent standard for quantitative
lutetium-177 SPECT.
Methods: Four state-of-the-art SPECT/CT systems were included: Discovery™ NM/
CT 670Pro (GE Healthcare), Symbia Intevo™, and two Symbia™ T16 (Siemens
Healthineers). Quantitative accuracy and inter-system variations were evaluated
by repeatedly scanning a cylindrical phantom with 6 spherical inserts (0.5 – 113
ml). A sphere-to-background activity concentration ratio of 10:1 was used.
Acquisition settings were standardized: medium energy collimator, body contour
trajectory, photon energy window of 208 keV (± 10%), adjacent 20% lower scatter
window, 2 × 64 projections, 128 × 128 matrix size, and 40 s projection time.
Reconstructions were performed using GE Evolution with Q.Metrix™, Siemens
xSPECT Quant™, Siemens Broad Quantification™ or Siemens Flash3D™ algorithms
using vendor recommended settings. In addition, projection data were reconstructed
using Hermes SUV SPECT™ with standardized reconstruction settings to obtain a
vendor-neutral quantitative reconstruction for all systems. Volumes of interest (VOI) for
the spheres were obtained by applying a 50% threshold of the sphere maximum voxel
value corrected for background activity. For each sphere, the mean and maximum
recovery coefficient (RCmean and RCmax) of three repeated measurements was
calculated, defined as the imaged activity concentration divided by the actual activity
concentration. Inter-system variations were defined as the range of RC over all systems.
Results: RC decreased with decreasing sphere volume. Inter-system variations with
vendor-specific reconstructions were between 0.06 and 0.41 for RCmean depending on
sphere size (maximum 118% quantification difference), and improved to 0.02–0.19 with
vendor-neutral reconstructions (maximum 38% quantification difference).
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Conclusion: This study shows that eliminating sources of possible variation drastically
reduces inter-system variation in quantification. This means that absolute SPECT
quantification for 177Lu is feasible in a multi-center and multi-vendor setting; however,
close agreement between vendors and sites is key for multi-center dosimetry and
quantitative biomarker studies.
Introduction
Quantitative SPECT imaging in targeted radionuclide therapy with lutetium-177
(177Lu) holds great potential for dosimetry-based individualized treatment and may im-
prove prediction of therapy response, prevention of toxicity effects and treatment
follow-up. With the advent of 177Lu-PSMA therapy [1–4], it is expected that dosimetry
will play a pivotal role in the reliable determination of dose-response relationships in
tumors. But also our understanding of biomarker studies and already well-established
radionuclide therapies in neuroendocrine tumors [5–9] may profit from optimized
quantitative SPECT imaging for sophisticated dosimetry.
SPECT quantification is considered less straightforward than PET quantification [10,
11]. This can be explained by several factors including lower sensitivity due to the neces-
sary use of a collimator, the need for more complicated scatter and attenuation correction
[11] and a lower resolution creating partial volume effects. Several studies investigated the
quantitative performance of SPECT for a variety of radionuclides, including technetium-
99m (99mTc) [12, 13], indium-111 (111In) [14–16], iodine-131 (131I) [17], yttrium-90 (90Y),
or a combination of these [18, 19] and concluded that quantification is possible, be it with
certain limitations, for example, with regard to small structures as a result to the partial
volume effect. Beauregard et al. looked into the quantitative accuracy of 177Lu on one
SPECT/CT system [20] and found that this could yield more accurate dosimetry estimates
than planar imaging. Hippeläinen et al. compared the results of different ordered subset
expectation maximization (OSEM) reconstruction algorithms [21] and concluded that
alignment was best when the images were corrected for attenuation, scatter, and detector
and collimator response. Various SPECT/CT vendors have responded to the increasing
need for SPECT quantification and now commercially offer software packages for quanti-
fication of several radionuclides including 177Lu [22–24].
However, standardization of protocols such that quantitative results can be reliably
compared between systems requires more insight in their quantitative accuracy and
performance. This is key for, e.g., multi-center research trials involving absolute
SPECT quantification, especially those aimed towards dosimetry. Our previous study
compared quantification for SPECT/CT systems from different vendors at different
imaging centers for technetium-99 m and showed that standardizing reconstruction
decreased inter-system variability [25]. The aim of this study is to extend these find-
ings to 177Lu. The quantitative accuracy and inter-system variability of recovery coef-
ficients (RC) were determined using phantom experiments and the effects of lesion
volume and reconstruction algorithm on RC were investigated. The results of these
comparisons can be used as input for a vendor-independent standard for absolute
quantitative SPECT of 177Lu.
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Methods
SPECT/CT systems
Four SPECT/CT systems from two manufacturers were included in this study: a Dis-
covery NM/CT 670 Pro (GE Healthcare, Milwaukee, USA), a Symbia Intevo Bold, and
two Symbia T16’s (Siemens Healthineers, Erlangen, Germany) (Table 1). Three out of
four systems had commercial software packages for quantification installed, as listed in
Table 2.
Table 1 Main properties of the dual headed SPECT/CT systems used in this study
System General Electric
Discovery NM/CT
670 Pro
Siemens
Symbia Intevo Bold
Siemens
Symbia T16 system 1
Siemens
Symbia T16 system 2
Imaging
center
Leiden University
Medical Center
University Medical
Center Utrecht
Radboud University
Medical Center
Erasmus University
Medical Center
SPECT
detector
3/8″ NaI crystal
59 PMT*
40 × 54 cm FOV*
3/8″ NaI crystal
59 PMT*
38.7 × 53.3 cm FOV*
3/8″ NaI crystal
59 PMT*
38.7 × 53.3 cm FOV*
3/8″ NaI crystal
59 PMT*
38.7 × 53.3 cm FOV*
CT 16-slice 16-slice 16-slice 16-slice
*PMT photomultiplier tube, FOV field of view
Table 2 Reconstruction/quantification parameters and processing software used in this study.
Quantification packages Q. Metrix, xSPECT Quant, and Broad quantification enable quantitative
reconstructions in the scanner software
System Discovery NM/
CT 670 Pro
Symbia Intevo
Bold
Symbia T16
system 1
Symbia T16
system 2
All
(standardized)
Imaging center Leiden University
Medical Center
University
Medical Center
Utrecht
Radboud
University
Medical Center
Erasmus
University
Medical Center
All
Reconstruction OSEMa +
Evolution with
PSFa correction
WCGa + xSPECT
with PSFa
correction
OSEMa + Flash 3D
with PSFa
correction
OSEMa + Hybrid
Recon V3.0.0
with PSFa
correction
OSEMa + Hybrid
Recon V3.0.0
with PSFa
correction
Quantification Q.Metrix xSPECT Quant/
Broad
Quantificationb
Manual analysis Hermes SUV
SPECT
Hermes SUV
SPECT
Iterations 9d 6 4 5 5
Subsets 10 8 8 16 16
Post-
reconstruction
filter
None 5mm (Gaussian) 4 mm (Gaussian) 5 mm (Gaussian) 5 mm (Gaussian)
Attenuation
correction
CT basedc CT basedc CT basedc CT basedc CT basedc
Scatter
Correction
DEWa (170 ± 10%) DEWa (170 ± 10%) DEWa (170 ± 10%) Monte
Carlo-based
Monte
Carlo-based
Reconstruction
voxel size
2.0 × 2.0 × 2.0
mm3 e
4.9 × 4.9 × 4.9
mm3
4.8 × 4.8 × 4.8
mm3
4.8 × 4.8 × 4.8
mm3
4.8 × 4.8 × 4.8
mm3
a OSEM ordered subset expectation maximization; WCG weighted conjugate gradient, PSF point spread function, DEW
double energy window
b For xSPECT Quant and Broad quantification separate measurements were performed
c Bilinear conversion of HU into attenuation coefficients at 208 keV
d Settings were not according to vendor recommendation but to the literature [13]
e Interpolation to 2.0 × 2.0 × 2.0 mm3 voxels by Q. Metrix for quantification, as recommended by the vendor
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Phantom
A modified cylindrical Jaszczak phantom (Fig. 1) was used, with a background compartment
volume of approximately 6.7 l and regular inserts replaced by 6 spherical inserts representing
various lesion sizes with inner diameters (and volumes) of 13mm (1.2ml), 17mm (2.6ml),
22mm (5.6ml), 28mm (11.5ml), 37mm (26.5ml), and 60mm (113ml).
The spheres and background compartment were filled with a homogeneous solution of
177Lu in water with an activity concentration of approximately 750 kBq/ml for the spheres
and 75 kBq/ml for the background compartment, resulting in a sphere-to-background ratio of
10:1. The concentrations were based upon the expected lesion uptake in lutetium therapy [2,
26]. The solution was saturated with a 50 mM ethylenediaminetetraacetic acid (EDTA) solu-
tion to prevent precipitation of lutetium. Enabled by the long half-life time of 177Lu (T1/2 =
665 days), user preparation differences were excluded by the study set-up, as the phantom
was filled once before being sent around to the participating centers. The time between first
and last measurement was 74.7 h, and during acquisition, the measurement time per angle
was adjusted for activity decay to obtain similar count statistics for each measurement.
To check for possible quantification differences caused by the use of different dose cali-
brators, a syringe filled with the same solution with an activity of 29.0MBq 177Lu was
measured in each center and compared to the activity measured in the reference center.
Acquisition
Images were acquired with a Medium Energy General Purpose (MEGP) or Medium
Energy Low Penetration (MELP) collimator (Additional file 1: Table S1). Acquisition set-
tings were harmonized across all systems according to MIRD Pamphlet No. 26 [27]: body
contour trajectory, a photon energy window of 208 keV (± 10%), adjacent 20% lower scat-
ter window, 2 × 64 projections, a 128 × 128 matrix size, and a reference projection time of
40 s. On each system, the measurement was repeated three times to assess repeatability.
Reconstruction
Reconstructions were performed with vendor/center specific 3D iterative reconstruction algo-
rithms and quantification packages (Table 2). The reconstructions were performed with scat-
ter correction, CT-based attenuation correction (Additional file 1: Table S2) and resolution
recovery, using vendor recommended settings (Table 2). In addition to vendor/center specific
reconstructions, all raw data were reconstructed with a vendor neutral-reconstruction
Fig. 1 The phantom used to determine the recovery coefficients. The second image is a CT slice of the
phantom on which the order of the spheres can be seen
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algorithm (Hybrid Recon v3.0.0, Hermes SUV SPECT™, Stockholm, Sweden), with standard-
ized reconstruction settings (Table 2) to obtain vendor-neutral quantitative reconstructions
for all systems.
Calibration factor
All SPECT/CT systems were cross-calibrated for 177Lu with the in-house dose calibrator ac-
cording to the manufacturer’s guidelines or to the center’s standard practice (Additional file 1:
Table S3). An exception was the Symbia Intevo Bold (xSPECT) quantification calibration,
which is different from the other calibration methods, as it makes use of a (by manufacturer)
included 75Se calibrated sensitivity precision source instead of a 177Lu source. All dose calibra-
tors used in this study to cross-calibrate the SPECT systems undergo regular quality control
according to national guidelines [28].
To determine the calibration factor for the vendor-neutral quantification method each site
performed a calibration according to the guidelines of this particular software vendor. Each
site scanned a homogeneous cylindrical phantom with a 6 to 7 l volume and approximately
500MBq 177Lu with the same acquisition protocol as used in the experiments. Volumes of
interest (VOIs) were drawn to obtain a calibration factor (CF):
CF
cps
ml
kBq
ml
2
64
3
75 ¼
μ
t∙n∙ν
 
C
; ð1Þ
where μ is the mean voxel value in counts in the reconstructed image, t is the time per
projection, n is the number of projections, ν is the voxel size and C is the actual activity
concentration in the phantom.
Image analysis
Image analyses were performed using in-house developed software in Python. This
script uses the SimpleITK toolkit region growing algorithm to determine the sphere
VOI [29, 30]. The VOIs were obtained by applying a 50% threshold of the sphere max-
imum voxel value with a correction for the background activity [31]:
VOIthresh; j ¼ 0:5∙ VOI max; j þ VOImean;bg
  ð2Þ
where VOIthresh,j is the VOI threshold voxel value of sphere j, VOImax,j is the maximum voxel
value in the sphere VOI and VOImean,bg is the mean voxel value in the background VOI. The
background was determined by placing a single cylindrical VOI (diameter 9 cm, 5 cm height)
in a uniform region within the phantom. For each sphere VOI, the mean and maximum re-
covery coefficient (respectively RCmean and RCmax) were calculated, defined as the mean/max-
imum imaged activity concentration (Ai) over the three consecutive measurements, divided by
the actual activity concentration (Aa):
RCmean; j ¼ Ai; jAa; j ð3Þ
RC max; j ¼ Ai; max; jAa; j ð4Þ
The inter-system variability was assessed for each sphere diameter by the range of
the RC over all systems according to:
Peters et al. EJNMMI Physics             (2020) 7:9 Page 5 of 13
Range j ¼ RC j; max−RC j; min ð5Þ
where j is the sphere diameter. This range was calculated for both the RCmean and
RCmax.
This study included three systems of one vendor (Siemens), all consisting of (almost)
equal hardware. Therefore, it was possible to compare quantification differences within
one vendor as well, thereby focusing on differences between systems without the influ-
ence of their hardware.
Error analysis
Uncertainties were determined for both the CF and de RC according to the EANM
guidelines by Gear et al. [32]. The recovery coefficient curve as a function of sphere
volume was fitted with a 3-parameter logistic function.
Results
Calibration
Differences in activity in the syringe as determined by the dose calibrator in each center
were 1–4% (Table 3).
Table 4 shows the calibration factors of each system. The error in CF is assumed to
be within 5% since it is dominated by the uncertainty in the activity used in the cylin-
drical phantom. The activity was measured in a dose calibrator with an uncertainty
smaller than 5% (Table 3). In addition, the standard deviation in repeated measure-
ments of a 389 voxel-sized VOI used for the average voxel counts μ (Eq. 1) was 0.7%.
Recovery coefficient
The actual sphere-to-background activity concentration ratio based on dose calibrator
measurements was 9.4:1. The median recovery coefficient of the background compart-
ment for the five different vendor-specific reconstructions was 0.97 (range 0.92–1.06).
The center-specific SPECT reconstructions are shown in Fig. 2. Due to the low con-
trast compared to the background, the smallest sphere (13 mm diameter) is not or
barely visible. The recovery coefficients of the spheres (Fig. 3a–e) decreased with de-
creasing sphere diameter on all systems. The variability between systems for RCmean is
visualized in Fig. 3f by plotting median and range for all systems. A large variability was
found for spheres with a diameter ≤ 28mm with a total RC range of up to 0.41 for
(resulting in 118% quantification differences between systems) and 0.62 for RCmax
(139% quantification differences), especially when compared to the largest sphere diam-
eter (60 mm) that showed variability of 0.10 (11%) and 0.19 (15%) for RCmean and
RCmax respectively.
Table 3 Measured differences in activity of a syringe filled with 29.0 MBq 177Lu resulting from the
use of different dose calibrators as used for the given systems
System Deviation (compared to reference)
Symbia T16 system 1 (reference) 1.00
Discovery NM/CT 670 Pro 0.96
Symbia Intevo Bold, xSPECT Quant 1.01
Symbia T16 system 2 0.99
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The RC values were fitted with a 3-parameter logistic function as suggested in the
EANM guidelines [32]. The additional parameter was introduced to allow the logistic
function to reach asymptotic values different from unity. All curves showed a good cor-
relation with the data (Pearson R2 > 0.96).
Effect of reconstruction algorithm on recovery coefficients
The vendor-neutral SPECT reconstructions are shown in Fig. 4. Using this reconstruc-
tion algorithm on all data leads to visually more similar reconstructions. The median
recovery coefficient of the background compartment for the four different vendor-
specific reconstructions was 1.03 (range 0.91–1.07).
Figure 5 shows the recovery coefficient per system for the vendor-neutral reconstruc-
tions. By comparing Fig. 3 (vendor-specific) to Fig. 5 (vendor-neutral), a decrease in inter-
system variability can be seen. This was confirmed by a large decrease in range for all
sphere diameters ≤ 28mm for both RCmean (0.9 to 0.11, resulting in quantification differ-
ences between systems of up to 38%) and RCmax (0.12 to 0.17, resulting in quantification
differences of up to 46%) (Fig. 5). Figure 6 shows the inter-system variability (RC range)
Table 4 Calibration factor (CF) for each system for vendor-neutral quantification
System CF for Hermes SUV SPECT [cps/MBq]
Discovery NM/CT 670 Pro 6.2
Symbia Intevo Bold, xSPECT Quant 10.2
Symbia Intevo Bold, Broad Quantification 10.2
Symbia T16 system 1 10.3
Symbia T16 system 2 10.1
Fig. 2 SPECT images of the cylindrical phantom for all systems, reconstructed with vendor-specific
reconstruction algorithms
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for vendor-neutral and vendor-specific reconstructions. For the two largest spheres, the
inter-system variability slightly increased compared to the vendor-specific reconstruction,
resulting in quantification differences of up to 21%. When comparing systems within the
same vendor, the inter-system variations result in quantification differences for all sphere
sizes of up to 11% for RCmean, and 12% for RCmax. This illustrates the large effect of the
system hardware on quantification differences.
Discussion
This study shows that standardizing reconstruction settings decreases inter-system vari-
ability for quantification of 177Lu. This has important implications for multi-center
studies where quantification plays an important role in dosimetry studies.
In order to eliminate preparation differences, the phantom was prepared only once
and sent around to all participating centers. Furthermore, differences in activity mea-
surements were monitored by measuring a syringe filled with a known amount of 177Lu
at each center and using the first center as a reference. Since one of the purposes of
our study was to illustrate the differences in quantification between centers, the mea-
sured activity differences were not corrected to determine the RC. However, it was
found that for one center, the deviation in activity was 4%, which of course could also
Fig. 3 Recovery coefficient as a function of sphere diameter for all systems separately (a–e) and for all systems
combined (f), for data reconstructed with a vendor-specific algorithm. Median and range of three repetitive
measurements per system. a Discovery NM/CT 670 Pro. b Symbia Intevo Bold with xSPECT Quant. c Symbia
Intevo Bold with Broad Quantification. d Symbia T16 system 1. e Symbia T16 system 2. f Mean and standard
deviation. All data were fitted with a 3-parameter logistic function (dashed line: 95% CI), for the combined data
(f) also the 95% prediction interval is indicated (dashed area)
Fig. 4 SPECT images of the cylindrical phantom for all systems, reconstructed with a vendor-neutral algorithm
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affect the final quantification on the SPECT/CT system since the cross-calibration for
177Lu used for quantification was based on measurements on the center’s own dose
calibrator.
An adaptation of the Jaszczak phantom was used to determine the RC for different
sphere diameters. The varying sphere diameters represent different lesion sizes and can
give an estimate of the expected RC values for these lesions. For quantification as input
for dosimetry, one could consider using a correction factor for smaller lesions, which
show RC values well below a value of 1.0 [32].
In this study, reconstruction settings were used that are applied in clinical practice
for each center. These reconstruction settings were based mainly on the recommenda-
tions of the vendor, with possible adjustments by the center itself. These settings might
Fig. 5 Recovery coefficient as a function of sphere diameter for all systems separately (a–e) and for all
systems combined (f), for data reconstructed with a vendor-neutral algorithm. Median and range of three
repetitive measurements per system. a Discovery NM/CT 670 Pro. b Symbia Intevo Bold with xSPECT Quant.
c Symbia Intevo Bold with Broad Quantification. d Symbia T16 system 1. e Symbia T16 system 2. f Mean
and standard deviation for all systems combined. All data were fitted with a 3-parameter logistic function
(dashed line 95% CI), for the combined data (f) also the 95% prediction interval is indicated (dashed area)
Fig. 6 Comparison in range over all systems in RCmean (a) and RCmax (b) per sphere diameter for data
reconstructed with a vendor-specific algorithm versus a vendor-neutral algorithm. Third and fourth columns
give the same information but for systems of only one vendor, thus consisting of equal system hardware
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not be ideal for 177Lu quantification, and the number of iterations used in reconstruc-
tion, as well as the possible additional use of a post-reconstruction filter, might influ-
ence the quantification [33, 34]. Furthermore, Dewaraja and colleagues [35] pointed
out that post-reconstruction filtering is not desirable for quantifying total target activ-
ity, but acceptable when calculating 3D doses such as dose-volume histograms. This in-
dicates that the reconstruction and post-reconstruction settings used in this study
could be optimized further for quantification, possibly leading to better alignment in
quantification between different centers and systems.
Due to the low contrast compared to the background, the smallest sphere (13 mm
diameter) was barely visible. This limitation in system spatial resolution is in line with
the difficulty in quantification found by other studies [18, 19]. Therefore, the recovery
coefficients for this sphere volume should be interpreted with caution. Although it was
shown that the range in RC between systems decreased from the second-smallest to
the smallest sphere, it is expected that this is mainly due to the fact that the used seg-
mentation method, a threshold based on 50% of the maximum voxel value, was not
able to delineate a reliable VOI for the smallest sphere.
Image analysis was performed using an automated Python script that uses a
background-corrected 50% isocontour method based on the study of Frings and col-
leagues. Although a 42% isocontour method shows good recovery for both PET [36]
and SPECT [13], the background-corrected 50% isocontour method was chosen be-
cause of its high repeatability for PET in a multicenter settings [37] and to align our re-
sults as much as possible with the already existing standards for PET quantification
[38]. However, a recently published study by Ryu et al. [39] showed that the line pro-
files over active spheres of reconstructed SPECT images (using 99mTc and 177Lu)
showed a very different profile than the same spheres measured on PET (using 18F and
68Ga). This indicates that a 50% isocontour method might not be the most ideal solu-
tion threshold for contouring in SPECT and that a lower threshold might be more ap-
propriate as demonstrated by Collarino et al. [13]. However, the goal of this study was
to assess the effects of different quantitative SPECT imaging systems, independent of
the applied delineation method.
On the largest sphere, a low recovery coefficient was found, especially for recon-
struction with the vendor-neutral algorithm (Hermes SUV SPECT). This can most
probably be explained by the use of a 50% threshold for the VOI delineation, and
a contribution of the Gibbs artifact, which is clearly visible in Figs. 2 and 4. A typ-
ical strategy in handling Gibbs ringing artifacts is to reduce them with compro-
mised resolution [40, 41]. This reduction can be achieved by blurring the input
image so that the data do not contain high-frequency components, by reconstruc-
tion other than PSF or by using post-reconstruction Gaussian filtering. Although
not the goal of this study, reducing the Gibbs artifact might contribute to better
alignment in quantification between centers. Additionally, for the Discovery NM/
CT 670 Pro and the Symbia T16 system 1, the low RC for the largest sphere might
be explained by the number of iterations and subsets in the reconstruction settings.
This was according to the center’s standard settings which are based on vendor
recommendations and other literature on reconstruction settings [13]. However, in-
creasing the number of iterations might increase recovery and thereby improve
quantification accuracy.
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The values for RCmax are systematically over 1 for spheres with a diameter > 28mm. Al-
though an overshoot for RCmax was also found in other studies [13, 42], it was even higher
in this study (1.3 ± 0.2). This overshoot is not a statistical error but is most probably the
result of the resolution recovery algorithm that was used during reconstruction. This algo-
rithm was used in the standard reconstruction as recommended by the vendor.
For spheres with a diameter < 25 mm, RC quickly decreases as expected, mainly as a
result of partial volume effects. For GE Evolution reconstruction, no post-
reconstruction Gaussian smoothing filter was applied, which might explain a higher RC
for small sphere diameters. This high RC is also reflected in the large inter-system vari-
ations for small sphere diameters.
In this study, both RCmean and RCmax were determined and compared between systems.
The results could be used to work towards a normalization between centers and systems.
Depending on the application, the choice for either RCmean or RCmax as a tool for
standardization could be more applicable. For example in 18F-FDG PET quantification,
evaluation of treatment response is of main interest. In this case, this could be evaluated
by using the SUVmax and therefore standardization based on RCmax would be a logical
choice. For quantification of 177Lu, however, the most obvious application would be for
the use in dosimetry for radionuclide therapies with ligands such as 177Lu-PSMA for pros-
tate cancer or 177Lu-DOTATATE/DOTATOC for neuroendocrine tumors. This means a
VOI is needed to determine the accumulated activity, in which the mean voxel value is
the most relevant parameter. Therefore, we suggest that for normalization of 177Lu quan-
tification, the RCmean could be used as a tool for standardization between centers.
Although this study provides valuable insight in quantification differences between
systems, it only compared four SPECT/CT systems (five quantification methods). For
one vendor, three systems and four quantification methods were included in this study.
We showed that by eliminating the effect of system hardware, the inter-system variabil-
ity was greatly reduced. Standardizing the reconstruction algorithm led to a further de-
crease in intersystem variability. It is therefore paramount to harmonize SPECT/CT
image reconstructions in a multi-center/multi-vendor setting. These data can be used
as input to work towards a standard for quantification of 177Lu, but it needs to be ex-
panded to more centers and/or systems, preferably also across borders. We suggest that
further standardization could improve the alignment of quantification between different
SPECT/CT systems, comparable to the EARL accreditation program for 18F-FDG PET/
CT [42]. Still, it is important to realize that variability in quantification between
SPECT/CT systems will probably be larger than those found in this study, due to, for
example, patient positioning and patient size.
Conclusion
This study shows that absolute SPECT quantification for 177Lu is feasible in a multi-
center and multi-vendor setting. With standardized acquisition protocols but center-
specific data reconstruction algorithms, the inter-system variability (range in RC be-
tween systems) was as large as 0.41 and 0.62 for RCmean and RCmax, respectively. Stand-
ardizing reconstruction decreased this range to 0.19 and 0.32, respectively. Close
agreement between vendors and sites is key for multi-center dosimetry and quantitative
biomarker studies. This study serves as an important step towards a vendor-
independent standard for absolute quantification in SPECT/CT of 177Lu.
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